A5073517018- Diabetes Treatment and Management
- Diabetes Management and Research
- Metabolism, Diabetes, and Cancer
- Pancreatic function and diabetes
- Diabetes and associated disorders
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Pharmacology and Obesity Treatment
- Diet and metabolism studies
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Chronic Kidney Disease and Diabetes
- Cardiovascular Function and Risk Factors
- Diabetes Management and Education
- Blood Pressure and Hypertension Studies
- Diet, Metabolism, and Disease
- Obesity, Physical Activity, Diet
- Liver Disease Diagnosis and Treatment
- Heart Failure Treatment and Management
- Birth, Development, and Health
- Lipoproteins and Cardiovascular Health
- Growth Hormone and Insulin-like Growth Factors
- Adipose Tissue and Metabolism
- Renal Diseases and Glomerulopathies
- Chronic Disease Management Strategies
- Nitric Oxide and Endothelin Effects
- Antiplatelet Therapy and Cardiovascular Diseases
Hebrew University of Jerusalem
2015-2024
Hadassah Medical Center
2015-2024
Thrombolysis in Myocardial Infarction Study Group
2014-2024
Brigham and Women's Hospital
2014-2024
University Medical Center
1999-2024
Harvard University
2014-2023
Hadassah Academic College
2012-2022
Magna Graecia University
2021-2022
Israel Ministry of Health
2020-2021
Sheba Medical Center
2020-2021
It is unknown whether either the angiotensin-II–receptor blocker irbesartan or calcium-channel amlodipine slows progression of nephropathy in patients with type 2 diabetes independently its capacity to lower systemic blood pressure.
The cardiovascular safety and efficacy of many current antihyperglycemic agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear.We randomly assigned 16,492 patients with type 2 diabetes who had history of, or were at risk for, events to receive saxagliptin placebo followed them for median 2.1 years. Physicians permitted adjust other medications, agents. primary end point was composite death, myocardial infarction, ischemic stroke.A end-point event occurred in...
Guidelines and Expert Consensus documents aim to present management recommendations based on all of the relevant evidence a particular subject in order help physicians select best possible strategies for individual patient, suffering from specific condition, taking into account not only impact outcome, but also risk benefit ratio diagnostic or therapeutic procedure. The ESC guidelines production can be found website†. In brief, appoints experts field carry out comprehensive critical...
Reduced oxidation of fat leading to a positive balance could be factor in the development obesity. Twenty-four-hour respiratory quotient (RQ) was measured 152 nondiabetic Pima Indians fed weight-maintenance diet [87 males and 65 females; 27 +/- 6 yr (mean SD); 93.9 22.9 kg; 32 9% fat]. RQ varied from 0.799 0.903. Prior change body weight, 24-h energy balance, sex, percent explained 18% variance (P less than 0.001). In subgroup 66 siblings 28 families, family membership 28% remaining 0.05)....
Diabetes mellitus and heart failure frequently coexist. However, few diabetes trials have prospectively evaluated adjudicated as an end point.A total of 16 492 patients with type 2 a history of, or at risk cardiovascular events were randomized to saxagliptin placebo (mean follow-up, 2.1 years). The primary point was the composite death, myocardial infarction, ischemic stroke. Hospitalization for predefined component secondary point. Baseline N-terminal pro B-type natriuretic peptide measured...
OBJECTIVE—The aim of this trial was to evaluate the effects α-lipoic acid (ALA) on positive sensory symptoms and neuropathic deficits in diabetic patients with distal symmetric polyneuropathy (DSP). RESEARCH DESIGN AND METHODS—In multicenter, randomized, double-blind, placebo-controlled trial, 181 Russia Israel received once-daily oral doses 600 mg (n = 45) (ALA600), 1,200 47) (ALA1200), 1,800 (ALA1800) ALA 46) or placebo 43) for 5 weeks after a 1-week run-in period. The primary outcome...
In DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced composite end point of cardiovascular death/hospitalization for heart failure (HHF) a broad population patients with type diabetes mellitus. However, impact baseline left ventricular ejection fraction (EF) clinical benefit inhibition is unknown.In trial, (HF) status was collected from all patients, and EF when...
Background: Patients with diabetes have increased risk for adverse cardiovascular events. Angiotensin-converting enzyme inhibitors are protective in type 1 diabetes. However, no definitive studies examined the use of angiotensin-receptor blockers patients 2 and overt nephropathy. The primary outcomes Irbesartan Diabetic Nephropathy Trial were doubling serum creatinine levels, end-stage renal disease, death from any cause. Objective: To compare rates events among diabetic nephropathy who...
OBJECTIVE—Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus (HEART2D) is a multinational, randomized, controlled trial designed to compare the effects of prandial versus fasting glycemic control risk for cardiovascular outcomes patients with type diabetes after acute myocardial infarction (AMI). RESEARCH DESIGN AND METHODS—Patients (type diabetes, aged 30–75 years) were randomly assigned within 21 days AMI 1)...
In December 2008, the U.S. Food and Drug Administration issued guidance to pharmaceutical industry setting new expectations for development of antidiabetes drugs type 2 diabetes. This expanded scope cost research necessary approval such by mandating long-term cardiovascular outcomes trials (CVOTs) safety. Since 9 CVOTs have been reported, 13 are under way, 4 terminated. Reassuringly, each completed demonstrated noninferiority their respective placebo primary (CV) composite end point....
Atrial fibrillation (AF) and atrial flutter (AFL) are associated with both diabetes mellitus its related comorbidities, including hypertension, obesity, heart failure (HF). SGLT2 (sodium-glucose cotransporter 2) inhibitors have been shown to lower blood pressure, reduce weight, salutary effects on left ventricular remodeling, hospitalization for HF cardiovascular death in patients type 2 mellitus. We therefore investigated whether could also the risk of AF/AFL.DECLARE-TIMI 58 (Dapagliflozin...
Background: Sodium glucose transporter-2 inhibitors reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus and a history atherosclerotic disease. Because their baseline risk, previous myocardial infarction (MI) may derive even greater benefit from sodium inhibitor therapy. Methods: DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events–Thrombolysis Myocardial Infarction 58) randomized 17 160 either established disease (n=6974) or...
The requirement to inject current basal insulin analogs at a fixed time each day may complicate adherence and compromise glycemic control. This trial evaluated the efficacy safety of varying daily injection degludec (IDeg), an ultra-long-acting insulin.This 26-week, open-label, treat-to-target enrolled adults (≥18 years) with type 2 diabetes who were either naïve receiving oral antidiabetic drugs (OADs) (HbA(1c) = 7-11%) or previously on ± OAD(s) 7-10%). Participants randomized 1) once-daily...
OBJECTIVE To assess treatment satisfaction and the effectiveness of a flash glucose monitoring (FGM) system in patients with type 2 diabetes using insulin. RESEARCH DESIGN AND METHODS A total 101 on multiple daily insulin injections (MDI) for at least 1 year were assigned randomly to FGM intervention (n = 53) or standard care (control) group 48) followed 10 weeks. Both groups instructed adjust their doses face-to-face telephone visits. Satisfaction treatment, quality life, comfort FGM,...
Elevated lipoprotein(a) (Lp[a]) is a putative causal risk factor for atherosclerotic cardiovascular disease (ASCVD). There are conflicting data as to whether Lp(a) may increase only in the presence of concomitant inflammation.